查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1356794

抗结核药物市场报告：2030 年趋势、预测与竞争分析

Anti-Tuberculosis Therapeutics Market Report: Trends, Forecast and Competitive Analysis to 2030
出版日期: | 出版商: Lucintel | 英文 150 Pages | 商品交期: 3个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

抗结核药物的趋势与预测

预计2030年，全球抗结核药物市场将达21亿美元，2024年至2030年年复合成长率为7.1%。该市场的主要促进因素是患病患者病率的增加、政府组织提高结核病意识的倡议以及新兴国家耐多药和广泛抗药性病例的迅速增加。全球抗结核药物市场未来性广阔，医院、专科诊所和居家医疗市场充满机会。

抗结核治疗市场洞察

Lucintel 预测，由于结核病患者数量不断增加以及越来越多地采用异烟肼治疗结核病，异烟肼预计将在预测期内实现最高增长。

医院将继续成为该市场的最大细分市场。

由于政府措施的扩大、仿製药製造商数量的增加以及该地区医疗基础设施的持续发展，预计亚太地区将在预测期内实现最高的增长。

本报告回答了 11 个关键问题：

  • Q.1. 细分市场中最有前途和高成长的机会是什么？
  • Q.2.哪个细分市场将以更快的速度成长？为什么？
  • Q.3.您认为哪些地区未来会出现更快的成长？为什么？
  • Q.4. 影响市场动态的主要要素有哪些？市场的主要挑战和商业风险是什么？
  • Q.5. 这个市场的商业风险和竞争威胁是什么？
  • Q.6.这个市场有哪些新趋势？为什么？
  • Q.7.市场客户需求有何改变？
  • Q.8. 该市场有哪些新发展以及哪些公司处于领先地位？
  • Q.9.这个市场的主要企业有哪些？主要企业采取哪些策略配合措施来发展业务？
  • Q.10. 该市场上的竞争产品有哪些，由于材料或产品替代导致市场占有率下降的威胁有多大？
  • Q.11.过去年度发生了哪些併购事件，对产业产生了哪些影响？

目录

第1章执行摘要

第2章全球抗结核药物市场：市场动态

  • 简介、背景、分类
  • 供应链
  • 产业促进因素与挑战

第3章2018-2030年市场趋势及预测分析

  • 宏观经济趋势（2018-2023）与预测（2024-2030）
  • 全球抗结核药物市场趋势（2018-2023）与预测（2024-2030）
  • 按类型分類的全球抗结核药物市场
    • 活动性结核病
    • 潜伏性结核病
    • 其他的
  • 按药物类别分類的全球抗结核药物市场
    • 异烟肼
    • 利福平
    • 依三丁醇
    • 吡嗪酰胺
    • 氟喹诺酮类药物
    • 贝达喹啉
    • 氨基糖苷类
    • 硫代酰胺
    • 环胜肽
  • 全球抗结核药物市场（依最终用途）
    • 医院
    • 专科诊所
    • 居家护理
    • 其他的

第4章2018-2030年分地区市场趋势及预测分析

  • 全球抗结核药物市场区域分布
  • 北美抗结核药物市场
  • 欧洲抗结核药物市场
  • 亚太地区抗结核药物市场
  • 其他区域抗结核药物市场

第5章竞争分析

  • 产品系列分析
  • 营运整合
  • 波特五力分析

第6章成长机会与策略分析

  • 成长机会分析
    • 按类型分類的全球抗结核药物市场成长机会
    • 按药物类别分類的全球抗结核药物市场成长机会
    • 全球抗结核治疗市场成长机会（依最终用途）
    • 全球抗结核药物市场按地区成长机会
  • 全球抗结核药物市场的新趋势
  • 战略分析
    • 新产品开发
    • 扩大全球抗结核药物市场的产能
    • 全球抗结核药物市场的合併、收购与合资
    • 认证和许可

第7章主要企业概况

  • Lupin
  • Macleods
  • Otsuka
  • Johnson & Johnson
  • Sequella
  • Novartis
  • Akorn
  • Fresenius SE
  • Viatris
简介目录

Anti-Tuberculosis Therapeutics Trends and Forecast

The future of the global anti-tuberculosis therapeutics market looks promising with opportunities in the hospital, specialty clinic, and homecare markets. The global anti-tuberculosis therapeutics market is expected to reach an estimated $2.1 billion by 2030 with a CAGR of 7.1% from 2024 to 2030. The major drivers for this market are growing prevalence of tuberculosis, increasing initiative from government organization towards tuberculosis awareness, and surging incidence of MDR and XDR cases in developing countries.

A more than 150-page report is developed to help in your business decisions.

Anti-Tuberculosis Therapeutics by Segment

The study includes a forecast for the global anti-tuberculosis therapeutics by type, drug classes, end use, and region.

Anti-Tuberculosis Therapeutics Market by Type [Shipment Analysis by Value from 2018 to 2030]:

  • Active TB
  • Latent TB
  • Others

Anti-Tuberculosis Therapeutics Market by Drug Classes [Shipment Analysis by Value from 2018 to 2030]:

  • Isoniazid
  • Rifampin
  • Ethambutol
  • Pyrazinamide
  • Fluoroquinolones
  • Bedaquiline
  • Amynoglycosides
  • Thioamides
  • Cyclic Peptides
  • Others

Anti-Tuberculosis Therapeutics Market by End Use [Shipment Analysis by Value from 2018 to 2030]:

  • Hospitals
  • Specialty Clinics
  • Homecare
  • Others

Anti-Tuberculosis Therapeutics Market by Region [Shipment Analysis by Value from 2018 to 2030]:

  • North America
  • Europe
  • Asia Pacific
  • The Rest of the World

List of Anti-Tuberculosis Therapeutics Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies anti-tuberculosis therapeutics companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the anti-tuberculosis therapeutics companies profiled in this report include-

  • Lupin
  • Macleods
  • Otsuka
  • Johnson & Johnson
  • Sequella
  • Novartis
  • Akorn
  • Fresenius Se
  • Viatris

Anti-Tuberculosis Therapeutics Market Insights

Lucintel forecasts that isoniazid is expected to witness highest growth over the forecast period due to increasing cases of tuberculosis and rising adoption of isoniazid for the treatment of tuberculosis.

Within this market, hospitals will remain the largest segment due to .

APAC is expected to witness highest growth over the forecast period due to growing government intiatives, increasing number of generic manufacturers, and on-going development of healthcare infrastructure in the region.

Features of the Global Anti-Tuberculosis Therapeutics Market

Market Size Estimates: Anti-tuberculosis therapeutics market size estimation in terms of value ($B).

Trend and Forecast Analysis: Market trends (2018 to 2023) and forecast (2024 to 2030) by various segments and regions.

Segmentation Analysis: Anti-tuberculosis therapeutics market size by type, drug classes, end use, and region. in terms of value ($B).

Regional Analysis: Anti-tuberculosis therapeutics market breakdown by North America, Europe, Asia Pacific, and Rest of the World.

Growth Opportunities: Analysis of growth opportunities in different types, drug classes, end uses, and region.s for the anti-tuberculosis therapeutics market.

Strategic Analysis: This includes M&A, new product development, and competitive landscape of the anti-tuberculosis therapeutics market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

FAQ

Q.1. What is the anti-tuberculosis therapeutics market size?

Answer: The global anti-tuberculosis therapeutics market is expected to reach an estimated $2.1 billion by 2030.

Q.2. What is the growth forecast for anti-tuberculosis therapeutics market?

Answer: The global anti-tuberculosis therapeutics market is expected to grow with a CAGR of 7.1% from 2024 to 2030.

Q.3. What are the major drivers influencing the growth of the anti-tuberculosis therapeutics market?

Answer: The major drivers for this market are growing prevalence of tuberculosis, increasing initiative from government organization towards tuberculosis awareness, and surging incidence of MDR and XDR cases in developing countries.

Q.4. What are the major segments for anti-tuberculosis therapeutics market?

Answer: The future of the anti-tuberculosis therapeutics market looks promising with opportunities in the hospital, specialty clinic, and homecare markets.

Q.5. Who are the key Anti-Tuberculosis Therapeutics Market companies?

Answer: Some of the key anti-tuberculosis therapeutics companies are as follows:

  • Lupin
  • Macleods
  • Otsuka
  • Johnson & Johnson
  • Sequella
  • Novartis
  • Akorn
  • Fresenius SE
  • Viatris

Q.6. Which anti-tuberculosis therapeutics market segment will be the largest in future?

Answer: Lucintel forecasts that isoniazid is expected to witness highest growth over the forecast period due to increasing cases of tuberculosis and rising adoption of isoniazid for the treatment of tuberculosis.

Q.7. In anti-tuberculosis therapeutics market, which region is expected to be the largest in next 5 years?

Answer: APAC is expected to witness highest growth over the forecast period due to growing government intiatives, increasing number of generic manufacturers, and on-going development of healthcare infrastructure in the region.

Q.8. Do we receive customization in this report?

Answer: Yes, Lucintel provides 10% customization without any additional cost.

This report answers following 11 key questions:

  • Q.1. What are some of the most promising, high-growth opportunities for the anti-tuberculosis therapeutics market by type (active TB, latent LB, and others), drug classes (isoniazid, rifampin, ethambutol, pyrazinamide, fluoroquinolones, bedaquiline, amynoglycosides, thioamides, cyclic peptides, and others), end use (hospitals, specialty clinics, homecare, and others), and region. (North America, Europe, Asia Pacific, and the Rest of the World)?
  • Q.2. Which segments will grow at a faster pace and why?
  • Q.3. Which region will grow at a faster pace and why?
  • Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
  • Q.5. What are the business risks and competitive threats in this market?
  • Q.6. What are the emerging trends in this market and the reasons behind them?
  • Q.7. What are some of the changing demands of customers in the market?
  • Q.8. What are the new developments in the market? Which companies are leading these developments?
  • Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
  • Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
  • Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Global Anti-Tuberculosis Therapeutics Market : Market Dynamics

  • 2.1: Introduction, Background, and Classifications
  • 2.2: Supply Chain
  • 2.3: Industry Drivers and Challenges

3. Market Trends and Forecast Analysis from 2018 to 2030

  • 3.1. Macroeconomic Trends (2018-2023) and Forecast (2024-2030)
  • 3.2. Global Anti-Tuberculosis Therapeutics Market Trends (2018-2023) and Forecast (2024-2030)
  • 3.3: Global Anti-Tuberculosis Therapeutics Market by Type
    • 3.3.1: Active TB
    • 3.3.2: Latent TB
    • 3.3.3: Others
  • 3.4: Global Anti-Tuberculosis Therapeutics Market by Drug Classes
    • 3.4.1: Isoniazid
    • 3.4.2: Rifampin
    • 3.4.3: Ethambutol
    • 3.4.4: Pyrazinamide
    • 3.4.5: Fluoroquinolones
    • 3.4.6: Bedaquiline
    • 3.4.7: Amynoglycosides
    • 3.4.8: Thioamides
    • 3.4.9: Cyclic Peptides
  • 3.5: Global Anti-Tuberculosis Therapeutics Market by End Use
    • 3.5.1: Hospitals
    • 3.5.2: Specialty Clinics
    • 3.5.3: Homecare
    • 3.5.4: Others

4. Market Trends and Forecast Analysis by Region from 2018 to 2030

  • 4.1: Global Anti-Tuberculosis Therapeutics Market by Region
  • 4.2: North American Anti-Tuberculosis Therapeutics Market
    • 4.2.2: North American Anti-Tuberculosis Therapeutics Market by End Use: Hospitals, Specialty Clinics, Homecare, and Others
  • 4.3: European Anti-Tuberculosis Therapeutics Market
    • 4.3.1: European Anti-Tuberculosis Therapeutics Market by Drug Classes: Isoniazid, Rifampin, Ethambutol, Pyrazinamide, Fluoroquinolones, Bedaquiline, Amynoglycosides, Thioamides, Cyclic Peptides, and Others
    • 4.3.2: European Anti-Tuberculosis Therapeutics Market by End Use: Hospitals, Specialty Clinics, Homecare, and Others
  • 4.4: APAC Anti-Tuberculosis Therapeutics Market
    • 4.4.1: APAC Anti-Tuberculosis Therapeutics Market by Drug Classes: Isoniazid, Rifampin, Ethambutol, Pyrazinamide, Fluoroquinolones, Bedaquiline, Amynoglycosides, Thioamides, Cyclic Peptides, and Others
    • 4.4.2: APAC Anti-Tuberculosis Therapeutics Market by End Use: Hospitals, Specialty Clinics, Homecare, and Others
  • 4.5: ROW Anti-Tuberculosis Therapeutics Market
    • 4.5.1: ROW Anti-Tuberculosis Therapeutics Market by Drug Classes: Isoniazid, Rifampin, Ethambutol, Pyrazinamide, Fluoroquinolones, Bedaquiline, Amynoglycosides, Thioamides, Cyclic Peptides, and Others
    • 4.5.2: ROW Anti-Tuberculosis Therapeutics Market by End Use: Hospitals, Specialty Clinics, Homecare, and Others

5. Competitor Analysis

  • 5.1: Product Portfolio Analysis
  • 5.2: Operational Integration
  • 5.3: Porter's Five Forces Analysis

6. Growth Opportunities and Strategic Analysis

  • 6.1: Growth Opportunity Analysis
    • 6.1.1: Growth Opportunities for the Global Anti-Tuberculosis Therapeutics Market by Type
    • 6.1.2: Growth Opportunities for the Global Anti-Tuberculosis Therapeutics Market by Drug Classes
    • 6.1.3: Growth Opportunities for the Global Anti-Tuberculosis Therapeutics Market by End Use
    • 6.1.4: Growth Opportunities for the Global Anti-Tuberculosis Therapeutics Market by Region
  • 6.2: Emerging Trends in the Global Anti-Tuberculosis Therapeutics Market
  • 6.3: Strategic Analysis
    • 6.3.1: New Product Development
    • 6.3.2: Capacity Expansion of the Global Anti-Tuberculosis Therapeutics Market
    • 6.3.3: Mergers, Acquisitions, and Joint Ventures in the Global Anti-Tuberculosis Therapeutics Market
    • 6.3.4: Certification and Licensing

7. Company Profiles of Leading Players

  • 7.1: Lupin
  • 7.2: Macleods
  • 7.3: Otsuka
  • 7.4: Johnson & Johnson
  • 7.5: Sequella
  • 7.6: Novartis
  • 7.7: Akorn
  • 7.8: Fresenius SE
  • 7.9: Viatris